By in-licensing Lidocaine, a needle-free anesthetic ready for phase III testing from PowderJect and obtaining rights to PowderJect's needle-free drug delivery platform, the one-year-old pain management company AlgoRx has transformed itself overnight from a six-person shop with a pre-IND candidate to a drug-development company. Now it faces the challenges of late stage development and creating a pipeline with its injection technology platform. For a 15% stake in AlgoRx, PowderJect is glad to have finally divested its drug delivery business so it can focus on vaccines, an area which, through a series of acquisitions, is moving the company into the black.
Like a certain politician with an oddly similar name, pain
management company AlgoRx Pharmaceuticals Inc. has a new look and believes it is ready
for prime time.
This confidence comes on the heels of the young company's second in-licensing. In late March, AlgoRx bought the exclusive rights...
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.